Recursion Pharmaceuticals' AI-based approach has the potential to transform the pharmaceutical industry. However, it is still chasing clinical wins that would demonstrate the power of its strategy.

Recursion Pharmaceuticals (RXRX) added ~11% in the morning trading on Wednesday after J.P. Morgan upgraded the AI-driven biotech to Overweight from Neutral, citing a blockbuster sales potential for ...

In my book, Spoiled, I engage with a group of contemporary Asian American artists who expose and unravel the expectation that their work should heal and repair the wounds of racial difference as ...

Getting ready for coding interviews can feel like a big task, and figuring out the best way to tackle LeetCode is a common question. Many people find that using Python for their LeetCode solutions ...

Reversible programming languages and computing represent a forward‐looking paradigm in which every computational operation is designed to be invertible. In these systems, each transition from one ...

What if machines could not only learn but also teach themselves to become better with each iteration? This isn’t the plot of a sci-fi movie—it’s the reality unfolding in artificial intelligence ...

Abstract: This paper gives a nearly tight characterization of the quantum communication complexity of permutation-invariant Boolean functions. With such a characterization, we show that the quantum ...

Los Angeles—Artificial intelligence (AI)-based drug discovery continues to tout accelerated timelines and novel and effective treatments, yet today’s clinical success rates remain at a low 10%. On ...

On Aug. 8, Recursion Pharmaceuticals announced its intention to merge with Exscientia in an all-stock deal. Recursion Pharmaceuticals and Exscientia are both pharma-tech companies that aim to improve ...